{"id":"NCT02932462","sponsor":"Sun Pharmaceutical Industries, Inc.","briefTitle":"Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis","officialTitle":"A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site, Phase III Clinical Study to Evaluate the Efficacy and Safety of DSXS 1535 in Patients With Mild to Severe Scalp Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-03","primaryCompletion":"2016-12-01","completion":"2017-09-29","firstPosted":"2016-10-13","resultsPosted":"2018-12-06","lastUpdate":"2018-12-06"},"enrollment":373,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Scalp Psoriasis"],"interventions":[{"type":"DRUG","name":"DSXS","otherNames":["DSXS 1535"]},{"type":"DRUG","name":"Placebo","otherNames":["vehicle"]}],"arms":[{"label":"DSXS 1535","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study","primaryOutcome":{"measure":"Clinical Success in Patients With Moderate and Severe Scalp Psoriasis","timeFrame":"from baseline to study day 29","effectByArm":[{"arm":"DSXS 1535","deltaMin":41,"sd":null},{"arm":"Placebo","deltaMin":43,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.4557"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":180},"commonTop":["Headache","Nasopharyngitis","Eye irritation","Application site pruritus","Ocular discomfort"]}}